Please Scroll Down to See Forums Below
Bicept Injections?
- Thread starter mdlifter
- Start date
Whiskey said:
Lat injections, good lord.
Not me, I like it in the ....
Let me start this over!!
Not me, I always poke myself in the ........
Dammit!!!!!
One more time
The glutes are the easiest and least frightening place to shoot for me. Quads are easy, but that's as far as I'll go. I did calf once, never again.
If someone comes on this thread and says I hit my traps all the time, I'll freak the fuck out!!!!
concordsize
New member
i do bis once a week with no prob bro.
iamnikvanhelsing
New member
I injected BD Trinabol into my quad and couldn't walk properly for a week!! Quite funny actually cos after the first couple of days the pain went away but my leg still didnt work, I was walking like I had a wooden leg! Problem is that shit hurts like hell wherever you put it, delt, glute, quad. Ah well, no pain no gain!!
Tux said:Andy13, give me some proof. I've GOT proof, personal, medical, and professional, that site injections DO indeed work. So unless you've got a way to prove they don't work, which I know you don't, please shut up
Show me the proof. I am not interested in hearing testimony. I want medline ref's.
Tux
Well-known member
Try a few of these lol. Most prove that IGF-1 and GH DO indeed have increased localized effects on the tissues, muscles included, where they are injected. And as we all should know, most steroids, like nandrolone, trenbolone, etc, increase IGF-1 levels. I hate to prove you wrong bro, but it's right there in black and white. Sure, it doesn't work very well for most people, sure it CAN screw you up if you do it like Greg Valentino, but does localized injection work via IGF-1, GH, fascia-stretching, etc? Hell yes, and the medical evidence proves it. Deny it now.
Regulation and action of insulin-like growth factors at the cellular level
L S Phillips, J B Harp, S Goldstein, C I Pao
Proceedings of the Nutrition Society , 49(3):451-458 1990
Present understanding of IGF-1 as a growth factor mediating integration of nutritional-hormonal interactions indicates that IGF-1 acts in both an endocrine mode on distant targets and an autocrine-paracrine mode on local targets. In the liver, the combined presence of GH, insulin, and critical metabolic fuels such as essential amino acids results in increased levels of IGF-1 messenger RNA, increased production of a high-MW IGF-1 precursor, and increased release of IGF-1 into the circulation, permitting action on distant target tissues bearing specific receptors for IGF-1. The net effect is distant amplification of anabolic hormone action via IGF-1 acting in an endocrine mode. In extrahepatic tissues, both 'general' anabolic hormones (insulin and GH) as well as 'specific' hormones (e.g. gonadotropins) acting on a wide variety of targets (including fibroblasts and chondrocytes as well as granulosa and Leydig cells) promote both local secretion of IGF-1 and an increase in IGF-1 receptors. Local actions of IGF-1 then result in a secondary increase in both hormone receptors and hormone responses. The net effect is local amplification of hormone action via IGF-1 acting as a growth factor in an autocrine-paracrine mode.
Other References:
1. Hertoghe T. Growth hormone therapy in ageing adults 4th Annual meeting of the American Academy of anti-aging Medicine, Las Vegas December 1996.
2. Bouillanne O, Rainfray M, Tissandier O et al. Growth hormone in elderly people: an age-delaying drug? Fundan Clin Pharmacol 1996 10 (5) 416-30.
3. Merimee TJ. Growth hormone secretion and action. Endocrinology DeGroot et al (eds) New York, NY 1979.
4. Thoren M, Hilding M, Baxter RR et al. Serum insulin like growth factor 1(IGF1), IGF binding protein -1 and -3 and the acid labile subunit as serum markers of body composition during growth hormone therapy in adults with GH deficiency. J Clin Endorinol Metabol 1997; 82 (1): 223-8.
5. Johansson JO , Landin K, Johannsson G et al. Long term treatment with growth hormone decreases plasminogen acitivator and tissue plasminogen activator in growth hormone deficient adults. Thromb Haemost 1996; 76 (3): 422-8.
6. Boonen S, Lesaffre E, Aerssens J. Deficiency of the growth hormone insulin like growth factor 1 axis potentially involved in age related abnormalities in body composition. Gerontology 1996; 42 (6): 330-8.
7. Bengt-Ake Bengtsson. Effects of Growth Hormone Deficiency 4th Annual meeting of the American Academy of anti-aging Medicine, Las Vegas December 1996.
8. Jansen YJ, Frolich M, Roelfsema F. A low starting dose of genotropin in growth hormone deficient adults. J Clin Endocrinol Metab 1997; 82 (1): 129-35.
9. Terry CL. Human growth hormone replacement therapy in adults 4th Annual meeting of the American Academy of anti-aging Medicine, Las Vegas December 1996.
10. Klatz R, MD Grow Young with HGH Harper Collins New York, NY 1997.
11. Smith R. A new receptor involved in the control of growth hormone secretion 4th annual meeting American academy of anti-aging medicine Las Vegas 1996.
12. Kraemer WJ, Volek JS, Bush JA, et al. J.Appl.Physiol.85(4) 1544-1555,1998.
13. Daughaday WH,ed. Endocrine Control of Growth, New York:Elsevier,1981.
14. Tillmann V, Patel L, Gill MS, et al. Clin Endocrinol.53(3):329-336,2000.
15. Philips LS. Metabolism, 34:765-770,1985
16. Carroll PV, Christ ER, Umpleby AM, et al. Diabetes, 49(5):789-96,2000.
17. Zachwieja JJ, Yarasheski KE. Phys Ther. 79(1):76-82,1999.
18. Parkhouse WS, Coupland DC, Li C, Vanderhoek KJ. Mech Aging Dev.
77;113(2):75-83,2000.
19. Rasmussen BB, Tipton KD, Miller SL, et al. J.Appl.Physiol. 88:386-392,2000.
20. Jenkins PJ. Clin Endocrin. 50:683-689,1999.
21. Bamman MM, et al. Am J Physiol Endocrinol Metab. 280:E383-E390, 2001.
22. Nindl BC, et al. J Appl Physiol. 90:1319-1326, 2001.
Regulation and action of insulin-like growth factors at the cellular level
L S Phillips, J B Harp, S Goldstein, C I Pao
Proceedings of the Nutrition Society , 49(3):451-458 1990
Present understanding of IGF-1 as a growth factor mediating integration of nutritional-hormonal interactions indicates that IGF-1 acts in both an endocrine mode on distant targets and an autocrine-paracrine mode on local targets. In the liver, the combined presence of GH, insulin, and critical metabolic fuels such as essential amino acids results in increased levels of IGF-1 messenger RNA, increased production of a high-MW IGF-1 precursor, and increased release of IGF-1 into the circulation, permitting action on distant target tissues bearing specific receptors for IGF-1. The net effect is distant amplification of anabolic hormone action via IGF-1 acting in an endocrine mode. In extrahepatic tissues, both 'general' anabolic hormones (insulin and GH) as well as 'specific' hormones (e.g. gonadotropins) acting on a wide variety of targets (including fibroblasts and chondrocytes as well as granulosa and Leydig cells) promote both local secretion of IGF-1 and an increase in IGF-1 receptors. Local actions of IGF-1 then result in a secondary increase in both hormone receptors and hormone responses. The net effect is local amplification of hormone action via IGF-1 acting as a growth factor in an autocrine-paracrine mode.
Other References:
1. Hertoghe T. Growth hormone therapy in ageing adults 4th Annual meeting of the American Academy of anti-aging Medicine, Las Vegas December 1996.
2. Bouillanne O, Rainfray M, Tissandier O et al. Growth hormone in elderly people: an age-delaying drug? Fundan Clin Pharmacol 1996 10 (5) 416-30.
3. Merimee TJ. Growth hormone secretion and action. Endocrinology DeGroot et al (eds) New York, NY 1979.
4. Thoren M, Hilding M, Baxter RR et al. Serum insulin like growth factor 1(IGF1), IGF binding protein -1 and -3 and the acid labile subunit as serum markers of body composition during growth hormone therapy in adults with GH deficiency. J Clin Endorinol Metabol 1997; 82 (1): 223-8.
5. Johansson JO , Landin K, Johannsson G et al. Long term treatment with growth hormone decreases plasminogen acitivator and tissue plasminogen activator in growth hormone deficient adults. Thromb Haemost 1996; 76 (3): 422-8.
6. Boonen S, Lesaffre E, Aerssens J. Deficiency of the growth hormone insulin like growth factor 1 axis potentially involved in age related abnormalities in body composition. Gerontology 1996; 42 (6): 330-8.
7. Bengt-Ake Bengtsson. Effects of Growth Hormone Deficiency 4th Annual meeting of the American Academy of anti-aging Medicine, Las Vegas December 1996.
8. Jansen YJ, Frolich M, Roelfsema F. A low starting dose of genotropin in growth hormone deficient adults. J Clin Endocrinol Metab 1997; 82 (1): 129-35.
9. Terry CL. Human growth hormone replacement therapy in adults 4th Annual meeting of the American Academy of anti-aging Medicine, Las Vegas December 1996.
10. Klatz R, MD Grow Young with HGH Harper Collins New York, NY 1997.
11. Smith R. A new receptor involved in the control of growth hormone secretion 4th annual meeting American academy of anti-aging medicine Las Vegas 1996.
12. Kraemer WJ, Volek JS, Bush JA, et al. J.Appl.Physiol.85(4) 1544-1555,1998.
13. Daughaday WH,ed. Endocrine Control of Growth, New York:Elsevier,1981.
14. Tillmann V, Patel L, Gill MS, et al. Clin Endocrinol.53(3):329-336,2000.
15. Philips LS. Metabolism, 34:765-770,1985
16. Carroll PV, Christ ER, Umpleby AM, et al. Diabetes, 49(5):789-96,2000.
17. Zachwieja JJ, Yarasheski KE. Phys Ther. 79(1):76-82,1999.
18. Parkhouse WS, Coupland DC, Li C, Vanderhoek KJ. Mech Aging Dev.
77;113(2):75-83,2000.
19. Rasmussen BB, Tipton KD, Miller SL, et al. J.Appl.Physiol. 88:386-392,2000.
20. Jenkins PJ. Clin Endocrin. 50:683-689,1999.
21. Bamman MM, et al. Am J Physiol Endocrinol Metab. 280:E383-E390, 2001.
22. Nindl BC, et al. J Appl Physiol. 90:1319-1326, 2001.
Similar threads
